Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 5,801–5,900 of 10,906
Vaccination for COVID-19: Is it important and what should you know about it?
Wu, C.-P., Adhi, F., & Culver, D. A. (2021) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.88a.ccc076 · Cited by 8
Mueller-Enz, M., Woopen, C., Rahbani, G. K. A., Haase, R., Dunsche, M., Ziemssen, T., & Akgün, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1081933 · Cited by 8
Shi, W., Chen, S., Chi, F., Qiu, Q., Zhong, Y., Bian, X., Zhang, H., Xi, J., & Qian, H. (2022) · Advanced Therapeutics · doi:10.1002/adtp.202200239 · Cited by 10
Tadfor, Y., Nguyen-Hua, N., Bennett, H., Bos, A. J., & Smolinske, S. C. (2022) · Clinical Toxicology · doi:10.1080/15563650.2022.2147272 · Cited by 6
Self-citationNanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19
Valenzuela-Fernández, A., Cabrera-Rodríguez, R., Ciuffreda, L., Pérez-Yanes, S., Estévez‐Herrera, J., González‐Montelongo, R., Alcoba-Flórez, J., Trujillo‐González, R., de Artola, D. G.-M., Gil-Campesino, H., et al. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.1052436 · Cited by 10
Butt, A. A., Peng, Y., Shaikh, O. S., Omer, S. B., Mayr, F., & Talisa, V. B. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad195 · Cited by 10
Using nanomaterials to address SARS-CoV-2 variants through development of vaccines and therapeutics
Hangad, M. V., Keshvani, S., Kelpin, N., Walters-Shumka, J. P., Hood, M., Volk, C., Pal, D., & Willerth, S. M. (2022) · Frontiers in Materials · doi:10.3389/fmats.2022.1039247 · Cited by 8
Dou, X., Peng, M., Jiang, R., Li, W., & Zhang, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1174406 · Cited by 8
Nemeth, K. L., Yauney, E., Rock, J. M., Bievenue, R., Parker, M. M., & Styer, L. M. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.01336-22 · Cited by 6
Effects of cardiopulmonary bypass on immunoglobulin G antibody titres after SARS-CoV2 vaccination
Hayashi, R., Takami, Y., Fujigaki, H., Amano, K., Sakurai, Y., Akita, K., Yamana, K., Maekawa, A., Saito, K., & Takagi, Y. (2022) · Interactive Cardiovascular and Thoracic Surgery · doi:10.1093/icvts/ivac123 · Cited by 7
Multi-objective computational optimization of human 5′ UTR sequences
Yamada, K., Suga, K., Abe, N., Hashimoto, K., Tsutsumi, S., Inagaki, M., Hashiya, F., Abe, H., & Hamada, M. (2025) · Briefings in Bioinformatics · doi:10.1093/bib/bbaf225 · Cited by 10
Changes in COVID-19 vaccine hesitancy at different times among residents in Guangzhou, China
Chen, L., Li, Z., Lu, X., Deng, Y., Lu, K., Li, T., Lü, L., Wang, Z., & Lü, J. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1164475 · Cited by 7
Lagousi, T., Papadatou, I., Strempas, P., Chatzikalil, E., & Spoulou, V. I. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac396 · Cited by 8
ANCA-Associated Vasculitis after Moderna COVID-19 Vaccination
Gen, S., Iwai, T., Ohnari, S., Nobe, K., & Ikeda, N. (2023) · Case Reports in Nephrology · doi:10.1155/2023/4906876 · Cited by 9
Hamel, L., Poirier‐Gravel, F., Paré, M., Tardif, R., Comeau, M., Lavoie, P., Langlois, A., Goulet, M., Michaud, D., & D’Aoust, M. (2025) · Plant Biotechnology Journal · doi:10.1111/pbi.70075 · Cited by 8
Magalis, B. R., Rich, S. N., Tagliamonte, M. S., Mavian, C. N., Cash, M. N., Riva, A., Marini, S., Amador, D. M., Zhang, Y., Shapiro, J., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac197 · Cited by 7
Kroidl, I., Winter, S., Rubio‐Acero, R., Bakuli, A., Geldmacher, C., Eser, T. M., Deák, F., Horn, S., Zielke, A., Ahmed, M. I. M., et al. (2023) · Virology Journal · doi:10.1186/s12985-023-02167-z · Cited by 7
Predictors of impaired SARS-CoV-2 immunity in healthcare workers after vaccination with BNT162b2
Bertram, S., Blazquez‐Navarro, A., Seidel, M., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-10307-8 · Cited by 7
Alves, K., Kouassi, A., Plested, J. S., Kalkeri, R., Smith, K. C., Kaba, M., Nelson, J., Zhu, M., Cloney-Clark, S., Cai, Z., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127046 · Cited by 8
Araminda, G. N., & Ramatillah, D. L. (2022) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2022.v14s2.44747 · Cited by 7
Modulation of immune cells with mRNA nanoformulations for cancer immunotherapy
Han, J., & Park, J. (2023) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2023.103014 · Cited by 8
Dynamical intervention planning against COVID-19-like epidemics
Oliva, G., Schlueter, M., Munetomo, M., & Scala, A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0269830 · Cited by 7
Mutnal, M. B., Johnson, S., Mohamed, N., Abddelgader, R., Morales, L., Volz, M., Walker, K., Arroliga, A. C., & Rao, A. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27373 · Cited by 7
Addressing vaccine-preventable encephalitis in vulnerable populations
Piamonte, B. L. C., Easton, A., Wood, G. K., Davies, N. W. S., Granerød, J., Michael, B. D., Solomon, T., & Thakur, K. T. (2023) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001158 · Cited by 7
Lee, I., Lan, Y.-H., Wu, P., Wu, Y., Chen, Y.-H., Tseng, S.-C., Kuo, T.-J., Sun, C., Jan, J., Ma, H., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2149353 · Cited by 8
Takai, S., Nishida, H., Ito, H., et al. (2022) · International Journal of Urology · doi:10.1111/iju.14978 · Cited by 7
Fisher, M. J., & Psevdos, G. (2021) · American Journal of Infection Control · doi:10.1016/j.ajic.2021.06.010 · Cited by 11
Debnath, S. K., & Srivastava, R. (2022) · Frontiers in Nanotechnology · doi:10.3389/fnano.2021.813847 · Cited by 8
On the safety and effectiveness of COVID-19 vaccines, certainties and uncertainties
Escola Nacional de Saúde Pública Sérgio Arouca, F. O. C. (., de Oliveira, A. C. A. X., Delgado, I. F., Instituto Nacional de Controle de Qualidade em Saúde, F. O. C. (., Paumgartten, F. J. R., & Escola Nacional de Saúde Pública Sérgio Arouca, F. O. C. (. (2021) · doi:10.22239/2317-269x.01881 · Cited by 7
van der Toorn, W., Oh, D., Bourquain, D., et al. (2020) · medRxiv · doi:10.1101/2020.11.18.20233825 · Cited by 3
Faherty, E. A. G., Wilkins, K. J., Jones, S. E., Challa, A. P., Qin, Q., Chan, L., Olson‐Chen, C., Tarleton, J., Liebman, M., Mariona, F., et al. (2024) · Vaccines · doi:10.3390/vaccines12030289 · Cited by 8
Chen, I., Chang, L.-C., Wu, J., Lai, Y., Chang, Y.-J., Cheng, W.-J., & Hung, K. (2025) · Obesity Surgery · doi:10.1007/s11695-025-07900-x · Cited by 7
“The viral characteristics, vaccine availability [31], and treatment protocols have evolved substantially since those guidelines were established.”
Bhagavathula, A., Mahabadi, M. A., Tesfaye, W., Nayar, K., & Chattu, V. K. (2022) · Healthcare · doi:10.3390/healthcare10030438 · Cited by 5
Ouranidis, A., Choli‐Papadopoulou, T., Papachristou, E., Papi, R. M., & Kostomitsopoulos, N. G. (2021) · Vaccines · doi:10.3390/vaccines9080890 · Cited by 7
Herzog, N. K., Vasireddy, H., Drenner, D. A., & Rose, J. P. (2022) · Journal of Behavioral Medicine · doi:10.1007/s10865-022-00321-6 · Cited by 9
Massarweh, A., Tschernichovsky, R., Stemmer, A., Benouaich‐Amiel, A., Siegal, T., Eliakim‐Raz, N., Stemmer, S. M., & Yust‐Katz, S. (2022) · Journal of Neuro-Oncology · doi:10.1007/s11060-021-03911-7 · Cited by 7
Kvist‐Hansen, A., Pérez‐Alós, L., Al-Sofi, R. F., Heftdal, L. D., Hamm, S. R., Møller, D. L., Pries‐Heje, M. M., Fogh, K., Hansen, C. B., Hasselbalch, R. B., et al. (2023) · British Journal of Dermatology · doi:10.1093/bjd/ljad023 · Cited by 9
Mimura, W., Ishiguro, C., Terada-Hirashima, J., Matsunaga, N., Sato, S., Kawazoe, Y., Maeda, M., Murata, F., & Fukuda, H. (2023) · Journal of Epidemiology · doi:10.2188/jea.je20230106 · Cited by 6
Cardoso, S., de Sousa, F. P., Filho, P. D. A. P., & Azzoni, A. R. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07239-x · Cited by 7
Esen, M., Fischer-Herr, J., Gabor, J. J., Gaile, M., Fleischmann, W. A., Smeenk, G. W., de Moraes, R. A., Bélard, S., Calle, C. L., Woldearegai, T. G., et al. (2024) · Vaccines · doi:10.3390/vaccines12111288 · Cited by 9
Narongkiatikhun, P., Noppakun, K., Chaiwarith, R., Winichakoon, P., Vongsanim, S., Suteeka, Y., Pongsuwan, K., Kusirisin, P., Wongsarikan, N., Fanhchaksai, K., et al. (2023) · Vaccines · doi:10.3390/vaccines11040715 · Cited by 7
Almomani, E. Y., Hajjo, R., Qablan, A. M., Sabbah, D. A., & Al-Momany, A. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1211283 · Cited by 12
Utilization of genetic information for medicines development and equitable benefit sharing
Matsuyama, K., Kurihara, C., Crawley, F. P., & Kerpel‐Fronius, S. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1085864 · Cited by 10
SARS-CoV-2 in Transit: Characterization of SARS-CoV-2 Genomes From Venezuelan Migrants in Colombia
Patiño, L. H., Ballesteros, N., Muñoz, M., Castañeda, S., Hernández, C., Gomez, S., Flórez, C., Rico, A., Pardo, L., Hernández‐Pereira, C. E., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.07.069 · Cited by 7
Modeling and Predicting Antibody Durability for mRNA-1273 Vaccine for SARS-CoV-2 VariantsPreprint
Luo, G., Hu, Z., & Letterio, J. J. (2021) · medRxiv · doi:10.1101/2021.05.04.21256537 · Cited by 5
Vaccine Hesitancy and Behavioral Factors Associated With Vaccine Uptake
Omer, S. B., O’Leary, S. T., & Danchin, M. H. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00084-0 · Cited by 10
Clinical Features of COVID-19 Vaccine-Associated Autoimmune Hepatitis: A Systematic Review
Zhou, H., & Ye, Q. (2023) · Diseases · doi:10.3390/diseases11020080 · Cited by 9
Self-citationKim, J. G., Xu, J., Lee, D., Song, J., Lee, S., Hong, M. H., Zhu, J., Zhu, A. T., Patwari, K., Shim, E.-H., et al. (2026) · ACS Nano · doi:10.1021/acsnano.5c19036 · Cited by 8
Accountability in clinical trial diversity: The buck stops where?
Nephew, L. D. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100906 · Cited by 7
Mohapatra, S., Kumar, P. A., Farooq, U., Jain, P., Khan, R., Hassan, N., Shamim, A., Ansari, M. J., Alalaiwe, A. S., Aldawsari, M. F., et al. (2022) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2022.05.004 · Cited by 8
Ciccimarra, F., Luxi, N., Bellitto, C., L’Abbate, L., Raethke, M., van Hunsel, F. P. A. M., Lieber, T., Mulder, E., Riefolo, F., Dureau‐Pournin, C., et al. (2024) · Vaccines · doi:10.3390/vaccines12030241 · Cited by 11
Design aspects of COVID‐19 treatment trials: Improving probability and time of favorable events
Beyersmann, J., Friede, T., & Schmoor, C. (2021) · Biometrical Journal · doi:10.1002/bimj.202000359 · Cited by 7
Micronutrients for potential therapeutic use against COVID-19; a review
Giovane, R., Kinsley, S., & Keeton, E. (2021) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2021.09.744 · Cited by 7
COVID-19 Vaccine Effectiveness
Shader, R. I. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.04.016 · Cited by 8
Kinetics of SARS-CoV-2-Neutralising Antibodies of Residents of Long-Term Care Facilities
Moyet, J., Helle, F., Bourdenet, G., Joseph, C., Gubler, B., Deschasse, G., Defouilloy, I., Slovenski, T., François, C., Liabeuf, S., et al. (2021) · The journal of nutrition health & aging · doi:10.1007/s12603-021-1713-4 · Cited by 8
miRNAs in SARS-CoV-2 Infection: An Update
Azhar, A., Khan, W. H., Alhosaini, K. A., & Kamal, M. A. (2022) · Current Drug Metabolism · doi:10.2174/1389200223666220321102824 · Cited by 8
Kozak, A., Mikhaylov, G., Khodakivskyi, P. V., Goun, E. A., Turk, B., & Vasiljeva, O. S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15102464 · Cited by 7
Odainic, A., Spitzer, J., Szlapa, J., Schade, S., Krämer, T. J., Neuberger, J., Bode, C., Steinhagen, F., Schmithausen, R. M., Wilbring, G., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012231 · Cited by 7
Effects of Prior Infection with SARS-CoV-2 on B Cell Receptor Repertoire Response during Vaccination
Fraley, E., Khanal, S., Pierce, S. H., LeMaster, C., McLennan, R., Pastinen, T., & Bradley, T. (2022) · Vaccines · doi:10.3390/vaccines10091477 · Cited by 8
Sun, Y., Xu, S.-J., Zhou, Y.-F., Zhang, Y., Zhang, H., Le, T., Bai, Y.-Z., Rao, C.-H., Huo, S., Zhou, T., et al. (2025) · Journal of Virology · doi:10.1128/jvi.01472-25 · Cited by 9
“The success of mRNA vaccines against SARS-CoV-2 (15, 16), influenza (17), Zika virus (18), and porcine coronaviruses (e.g., PEDV, PDCoV) underscores their versatility and positions them as a paradigm-shifting solution for addressing various viral challenges (19, 20).”
Vaccination for COVID-19 control and considerations for Australia
MacIntyre, C. R. (2021) · Microbiology Australia · doi:10.1071/ma21009 · Cited by 7
Tapping the immunological imprints to design chimeric SARS-CoV-2 vaccine for elderly population
Biswas, A., Mandal, R. S., Chakraborty, S., & Maiti, G. (2021) · International Reviews of Immunology · doi:10.1080/08830185.2021.1925267 · Cited by 8
Not only lymphadenopathy: case of chest lymphangitis assessed with MRI after COVID 19 vaccine
Granata, V., Fusco, R., Vallone, P., Setola, S. V., Picone, C., Grassi, F., Patrone, R., Belli, A., Izzo, F., & Petrillo, A. (2022) · Infectious Agents and Cancer · doi:10.1186/s13027-022-00419-1 · Cited by 7
Igari, H., Asano, H., Murata, S., Yoshida, T., Kawasaki, K., Kageyama, T., Ikeda, K., Koshikawa, H., Okuda, Y., Urushihara, M., et al. (2022) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2022.07.010 · Cited by 7
Heterogeneity in Vaccinal Immunity to SARS-CoV-2 Can Be Addressed by a Personalized Booster Strategy
Stoddard, M., Yuan, L., Sarkar, S., Mangalaganesh, S., Nolan, R. P., Bottino, D. C., Hather, G., Hochberg, N. S., White, L. F., & Chakravarty, A. (2023) · Vaccines · doi:10.3390/vaccines11040806 · Cited by 8
Harnessing Biomaterials for Gene Therapy in Autoimmune Disease
Huang, W., Lu, J., Xue, Z., Tang, B., Tian, J., & Yang, L. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202503262 · Cited by 13
Immunogenicity and efficacy of a novel multi-patch SARS-CoV-2/COVID-19 vaccine candidate
Perdiguero, B., Marcos-Villar, L., López‐Bravo, M., Sánchez‐Cordón, P. J., Zamora, C., Valverde, J. R., Sorzano, C. Ó. S., Sin, L., Álvarez, E. A., Ramos, M., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1160065 · Cited by 8
Venous sinus thrombosis after the first dose of Pfizer BioNTech vaccine
Qureshi, M. I. A., Azam, B., Waheed, M. A., et al. (2022) · BMJ Case Reports · doi:10.1136/bcr-2021-247493 · Cited by 7
Sun, J., Wu, Y., Adjmi, M., Matthews, R. C., Kurian, A. A., Żak, M. M., Yoo, J., Mainkar, G., Lawless, H., Lu, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65344-4 · Cited by 7
COVID-19 after two doses of mRNA vaccines in kidney transplant recipients
Mehta, R. B., & Silveira, F. P. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16778 · Cited by 8
Schiaffino, S., Pinker, K., Cozzi, A., Magni, V., Athanasiou, A., Baltzer, P., Herrero, J. C., Clauser, P., Fallenberg, E. M., Forrai, G., et al. (2023) · Insights into Imaging · doi:10.1186/s13244-023-01453-2 · Cited by 7
Episomes and Transposases—Utilities to Maintain Transgene Expression from Nonviral Vectors
Kreppel, F., & Hagedorn, C. (2022) · Genes · doi:10.3390/genes13101872 · Cited by 8
Serwanga, J., Ankunda, V., Katende, J. S., Baine, C., Oluka, G. K., Odoch, G., Nantambi, H., Mugaba, S., Namuyanja, A., Ssali, I., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1348905 · Cited by 10
Abbasi, S., Matsui-Masai, M., Yasui, F., Hayashi, A., Tockary, T. A., Akinaga, S., Kohara, M., Kataoka, K., & Uchida, S. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.27.530188 · Cited by 9
Expert Perspectives on COVID-19 Vaccination for People Living with Multiple Sclerosis
Shin, R. K., Rammohan, K. W., & Williams, M. J. (2021) · Neurology and Therapy · doi:10.1007/s40120-021-00266-z · Cited by 7
Vosoughi, P., Naghib, S. M., Rahmanian, M., & Mozafari, M. R. (2025) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266325847241121034100 · Cited by 7
Chan, C. W., Yi, X., Lenza, M., Baldwin, A. D., Jakalski, J., Tešić, V., & Yeo, K.-T. J. (2021) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqab092 · Cited by 6
Vaccine-Associated Autoimmunity: From Clinical Signals to Immune Pathways
Peng, M., & Wang, Z. (2025) · Vaccines · doi:10.3390/vaccines13111112 · Cited by 10
“Vaccines can, in rare circumstances, disrupt immune tolerance through processes such as molecular mimicry, bystander activation, epitope spreading, or adjuvant-induced immune stimulation [8–11].”
Zhu, J. S., Wang, Q., & Huang, M. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1129183 · Cited by 8
Agbayani, G., Akache, B., Renner, T. M., et al. (2024) · European Journal of Immunology · doi:10.1002/eji.202350620 · Cited by 7
May polyethylene glycol be the cause of anaphylaxis to mRNA COVID-19 vaccines?
Junior, P. F. G.-B., & Kalil, J. (2021) · World Allergy Organization Journal · doi:10.1016/j.waojou.2021.100532 · Cited by 7
Concerns and challenges in clinics-guided nanovaccines design and applications
Gao, Y., Hua, S., Dong, X., Zhang, K., Zhang, X., & Yang, J. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.10.041 · Cited by 8
“BNT162b2 and mRNA-1273 have demonstrated safety and efficacy against SARS-CoV-2, achieving protection rates of 95% and 94.1%, respectively, in clinical trials (NCT04368728, NCT04470427) 154,155 .”
InfluentialLett, M. J., Otte, F., Hauser, D., Schön, J., Kipfer, E. T., Hoffmann, D., Halwe, N. J., Breithaupt, A., Ulrich, L., Britzke, T., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00992-z · Cited by 10
Wu, H., Dong, F., Li, Y., Liu, Z., Sun, J., Gao, B., Pehrsson, P. R., He, X., Wu, X., & Yu, L. L. (2025) · Food Research International · doi:10.1016/j.foodres.2025.115950 · Cited by 7
Hosseinian, S., Powers, K., Vasudev, M., Palma, A. M., de Assis, R., Jain, A., Horvath, P., Birring, P. S., Andary, R., Au, C., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.817345 · Cited by 9
Pei, Y., Li, J., Xu, S., & Xu, Y. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.828691 · Cited by 8
The Estimand Framework and Causal Inference: Complementary Not Competing Paradigms
Drury, T., Bartlett, J. W., Wright, D., & Keene, O. N. (2025) · Pharmaceutical Statistics · doi:10.1002/pst.70035 · Cited by 9
“In a COVID-19 vaccine trial [15] participants at high risk for SARS- CoV-2 infection or its complications were randomly assigned to receive two intramuscular injections of the mRNA-1273 vaccine or placebo 28 days apart.”
Piñana, J. L., García‐Sánz, R., Martino, R., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021006326 · Cited by 7
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.